Streetbeat News

Products Services

CYTK

Cytokinetics has announced the start of the ACACIA-HCM pivotal Phase 3 clinical trial of Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:31 am

ELDN

Eledon Pharmaceuticals has announced the publication of data showing that treatment with Tegoprubart promotes kidney and islet allograft survival and function in nonhuman primates.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:28 am

TLSA

A study validating the mechanism of action of Tiziana Life Sciences' intranasal Foralumab in Alzheimer's disease has been published in the Journal PNAS, following FDA IND clearance.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:25 am

NVDA

Iris Energy has released its monthly investor update, revealing plans to target next-generation computing and generative AI with NVIDIA's H100 GPUs. The company did not provide further details on the implementation or expected impact on its operations.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:24 am

TNGX

The FDA has cleared Tango Therapeutics' Investigational New Drug Application for TNG348, a treatment for BRCA 1/2 mutant and other HRD+ cancers.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:23 am

TRVN

Trevena has reported preliminary data from two proof-of-concept studies evaluating the S1PR mechanism of action and CNS target engagement of TRV045. The drug demonstrated a statistically significant analgesic effect in a capsaicin-induced model of neuropathic pain in a target engagement POC study.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:22 am

BCDA

BioCardia, Inc. (NASDAQ:BCDA) is exploring the development of a new Phase III clinical trial protocol for its CardiAMP autologous cell therapy for heart failure treatment, based on recent interim results. The company is considering replacing the third tier 6MWD with a more objective endpoint, potentially leading to a successful trial for product registration in the US. BioCardia is also focusing on accelerating its pivotal program for CardiAMP in Chronic Myocardial Ischemia.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:17 am

TNON

Tenon Medical has announced that the first patients have been treated with its new JIB Instrument Kit for the company's Catamaran SI Joint Fusion System.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:14 am

GLYC

Glycomimetics has begun dosing the first group of healthy volunteers in a Phase 1A study of GMI-1687. The study aims to evaluate the safety, tolerability, and pharmacokinetics of the drug. Initial results are expected by the end of Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:13 am

GSK

TNXP

Tonix Pharmaceuticals (TNXP) has committed to supplying Tosymra, a treatment for acute migraine, to meet potential increased demand following GlaxoSmithKline's (GSK) planned discontinuation of Imitrex nasal spray after January 2024.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:11 am